[go: up one dir, main page]

BR9712248A - Antagonista receptores de vitronectina - Google Patents

Antagonista receptores de vitronectina

Info

Publication number
BR9712248A
BR9712248A BR9712248A BR9712248A BR9712248A BR 9712248 A BR9712248 A BR 9712248A BR 9712248 A BR9712248 A BR 9712248A BR 9712248 A BR9712248 A BR 9712248A BR 9712248 A BR9712248 A BR 9712248A
Authority
BR
Brazil
Prior art keywords
receptor antagonist
vitronectin receptor
vitronectin
antagonist
receptor
Prior art date
Application number
BR9712248A
Other languages
English (en)
Other versions
BR9712248B1 (pt
Inventor
James Francis Callahan
Russel Donovan Cousins
Richard Mecullock Keenan
Chet Kwon
William Henry Miller
Irene Nijole Uzinkas
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR9712248A publication Critical patent/BR9712248A/pt
Publication of BR9712248B1 publication Critical patent/BR9712248B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI9712248-3A 1996-10-02 1997-10-01 antagonistas receptores de vitronectina. BR9712248B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2732096P 1996-10-02 1996-10-02
US4377697P 1997-04-11 1997-04-11
PCT/US1997/018001 WO1998014192A1 (en) 1996-10-02 1997-10-01 Vitronectin receptor antagonists

Publications (2)

Publication Number Publication Date
BR9712248A true BR9712248A (pt) 1999-08-24
BR9712248B1 BR9712248B1 (pt) 2010-06-29

Family

ID=26702318

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9712248-3A BR9712248B1 (pt) 1996-10-02 1997-10-01 antagonistas receptores de vitronectina.

Country Status (36)

Country Link
EP (1) EP0957917B1 (pt)
JP (2) JP4491072B2 (pt)
KR (1) KR100589578B1 (pt)
CN (1) CN1114403C (pt)
AP (1) AP1463A (pt)
AR (1) AR008878A1 (pt)
AT (1) ATE312089T1 (pt)
AU (1) AU733417B2 (pt)
BG (1) BG64581B1 (pt)
BR (1) BR9712248B1 (pt)
CA (1) CA2267224C (pt)
CO (1) CO4900046A1 (pt)
CY (1) CY2576B1 (pt)
CZ (1) CZ299076B6 (pt)
DE (1) DE69734833T2 (pt)
DK (1) DK0957917T3 (pt)
DZ (1) DZ2320A1 (pt)
EA (1) EA002419B1 (pt)
ES (1) ES2252775T3 (pt)
HU (1) HU229221B1 (pt)
ID (1) ID19623A (pt)
IL (1) IL129243A (pt)
MA (1) MA24361A1 (pt)
MY (1) MY137606A (pt)
NO (1) NO320194B1 (pt)
NZ (1) NZ334953A (pt)
PE (1) PE10499A1 (pt)
PL (1) PL190859B1 (pt)
RO (1) RO119881B1 (pt)
SA (1) SA98180936B1 (pt)
SK (1) SK285029B6 (pt)
TR (1) TR199900737T2 (pt)
TW (1) TW487702B (pt)
UA (1) UA60311C2 (pt)
UY (2) UY24735A1 (pt)
WO (1) WO1998014192A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
TR200000786T2 (tr) * 1997-09-24 2000-08-21 Smithkline Beecham Corporation Vitronektin reseptör antagonisti
CN1273529A (zh) * 1997-09-24 2000-11-15 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
US6372719B1 (en) 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
DE19842415A1 (de) * 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
IL143901A0 (en) * 1998-12-23 2002-04-21 Searle & Co Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
EP1150965A4 (en) * 1999-02-03 2002-05-15 Merck & Co Inc BENZAZEPINE DERIVATIVES AS ALPHA-V INTGRIN RECEPTOR ANTAGONISTS
MXPA01011052A (es) * 1999-04-30 2002-11-22 Univ Michigan Aplicaciones terapeuticas de benzodiazepinas pro-apoctoticas.
JP2003506452A (ja) * 1999-08-06 2003-02-18 スミスクライン・ビーチャム・コーポレイション 発作の治療に有用なビトロネクチン受容体アンタゴニスト
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
DE10027514A1 (de) * 2000-06-06 2002-01-03 Basf Ag Liganden von Integrinrezeptoren
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002060438A1 (en) 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
ES2319877T3 (es) * 2001-04-10 2009-05-14 Smithkline Beecham Corporation Metodo para inhibir la formacion de adherencias.
SE0101386D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab New compounds
CA2445679A1 (en) 2001-05-03 2002-11-14 Paul J. Coleman Benzazepinone alpha v integrin receptor antagonists
CA2464472C (en) 2001-10-22 2014-01-07 The Scripps Research Institute Antibody targeting compounds
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
WO2004089890A2 (en) * 2003-04-04 2004-10-21 Smithkline Beecham Corporation Process and intermediates for preparing benzazepines
EP1734996B1 (en) * 2004-04-02 2013-05-22 The Regents of The University of California Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006069079A2 (en) * 2004-12-21 2006-06-29 Smithkline Beecham Corporation Methods and formulations
PL1968594T3 (pl) * 2005-11-29 2011-03-31 Glaxosmithkline Llc Leczenie zaburzeń neowaskularyzacyjnych oka, takich jak zwyrodnienie plamki żółtej, rozszerzenie naczyń siatkówki w zespole Hippla i Lindaua, zapalenie błony naczyniowej oka i obrzęk plamki
JP5637855B2 (ja) 2007-11-08 2014-12-10 ザ ジェネラル ホスピタル コーポレイション 蛋白尿症の治療のための方法及び組成物
AU2008321770B2 (en) * 2007-11-16 2012-09-06 Ube Industries, Ltd. Benzazepinone compound
US8076475B2 (en) * 2008-03-06 2011-12-13 Glaxosmithkline Llc Process
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
AU2010231631A1 (en) 2009-03-30 2011-11-10 Ube Industries, Ltd. Pharmaceutical composition for treatment or prevention of ophthalmic diseases
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
CN102481347A (zh) 2009-07-24 2012-05-30 加州大学董事会 治疗和预防整合素αvβ5相关疾病的方法及组合物
WO2011062765A2 (en) 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
EP2325194A1 (en) * 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
CA3172692C (en) * 2020-04-26 2024-05-14 Jiangsu Nhwa Pharmaceutical Co., Ltd 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2152631A1 (en) * 1992-12-21 1994-07-07 William Edward Bondinell Bicyclic fibrinogen antagonists
AU702661B2 (en) * 1994-06-29 1999-02-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1996000574A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
US6008214A (en) * 1994-08-22 1999-12-28 Smithkline Beecham Corporation Bicyclic compounds
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Also Published As

Publication number Publication date
NO991590D0 (no) 1999-03-31
BG103299A (en) 2000-01-31
TW487702B (en) 2002-05-21
NO320194B1 (no) 2005-11-14
CA2267224C (en) 2007-03-13
CZ113299A3 (cs) 2000-03-15
DE69734833D1 (de) 2006-01-12
ID19623A (id) 1998-07-23
EP0957917A1 (en) 1999-11-24
JP2001501936A (ja) 2001-02-13
HUP9903769A3 (en) 2000-07-28
PE10499A1 (es) 1999-03-27
WO1998014192A1 (en) 1998-04-09
TR199900737T2 (xx) 1999-07-21
EP0957917B1 (en) 2005-12-07
MY137606A (en) 2009-02-27
CY2576B1 (en) 2008-07-02
UA60311C2 (uk) 2003-10-15
HUP9903769A2 (hu) 2000-03-28
BR9712248B1 (pt) 2010-06-29
DZ2320A1 (fr) 2002-12-28
SK285029B6 (sk) 2006-04-06
UY24735A1 (es) 1998-03-30
UY24935A1 (es) 2001-07-31
IL129243A (en) 2004-07-25
AU733417B2 (en) 2001-05-17
AP1463A (en) 2005-09-10
KR100589578B1 (ko) 2006-06-15
CN1238689A (zh) 1999-12-15
JP4491072B2 (ja) 2010-06-30
CZ299076B6 (cs) 2008-04-16
DE69734833T2 (de) 2006-07-13
EA199900356A1 (ru) 2000-02-28
SK42599A3 (en) 1999-12-10
CO4900046A1 (es) 2000-03-27
ATE312089T1 (de) 2005-12-15
CA2267224A1 (en) 1998-04-09
HK1023730A1 (en) 2000-09-22
CN1114403C (zh) 2003-07-16
EA002419B1 (ru) 2002-04-25
IL129243A0 (en) 2000-02-17
ES2252775T3 (es) 2006-05-16
NZ334953A (en) 2000-01-28
PL190859B1 (pl) 2006-02-28
HU229221B1 (en) 2013-09-30
JP2010006838A (ja) 2010-01-14
AU4746297A (en) 1998-04-24
SA98180936B1 (ar) 2006-05-30
PL332674A1 (en) 1999-09-27
DK0957917T3 (da) 2006-04-18
AP9901493A0 (en) 1999-03-31
MA24361A1 (fr) 1998-07-01
KR20000048816A (ko) 2000-07-25
NO991590L (no) 1999-05-31
AR008878A1 (es) 2000-02-23
BG64581B1 (bg) 2005-08-31
RO119881B1 (ro) 2005-05-30
EP0957917A4 (en) 2002-05-15

Similar Documents

Publication Publication Date Title
BR9712248A (pt) Antagonista receptores de vitronectina
BR9508178A (pt) Antagonistas de receptor de vitronectina
BR9612327A (pt) Antagonistas receptores de vitronectina
BR9612378A (pt) Antagonistas receptores de vitronectina
BR9612381A (pt) Antagonistas receptores vitronectina
NO972016D0 (no) Indolyl-Y-reseptorantagonister
BR9709952A (pt) Antagonistas de receptor de il-8
NO993350D0 (no) Vitronectin-reseptor-antagonister
NO986109D0 (no) IL-8 reseptor-antagonister
EP1000031A4 (en) VITRONECTIN RECEPTOR ANTAGONISTS
EP0810994A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS
EP0885205A4 (en) Fibrinogen Receptor Antagonists
BR9711140A (pt) Antagonistas receptores de il-8
ID24726A (id) Antagonis-antagonis reseptor trombin
NO20001514D0 (no) Vitronectin-reseptor-antagonist
NO20001515D0 (no) Vitronektin reseptor-antagonist
NO20004503D0 (no) Vitronectin-reseptor-antagonister
NO20001407D0 (no) Vitronectin-reseptor-antagonister
DK0906294T3 (da) Benzoxazinon-dopamin D4-receptor-antagonister
BR9507220A (pt) Antagonistas de receptores de endotelina
DZ2322A1 (fr) Antagonistes de récepteurs de vitronectine.
PT1146874E (pt) Antagonista de receptor da vitronectina
BR9609914A (pt) Antagonista do receptor de endotelina
NO20010620D0 (no) Vitronektinreseptor-antagonister
EP0957908A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/06/2010, OBSERVADAS AS CONDICOES LEGAIS.

B25D Requested change of name of applicant approved

Owner name: GLAXOSMITHKLINE LLC (US)

Free format text: NOME ALTERADO DE: SMITHKLINE BEECHAM CORPORATION

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE. PAGAR RESTAURACAO.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 21.6 PUBLICADO NA RPI 2343 DE 01/12/2015.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)